FDA Commissioner Stephen Hahn said the agency is considering permanently implementing some of the policies and processes adopted in response to the COVID-19 pandemic. Most of the changes "represent an acceleration of where we were headed before," including increased use of telemedicine in clinical trials, support for decentralized clinical studies and work on laboratory-developed tests, Hahn said.
Hahn: Some COVID-19 policies could be here to stay
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.